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ABSTRACT
Cystic fibrosis (CF) is caused by alterations in the CF transmembrane conduc-
tance regulator (CFTCR) gene. More than 1400 mutations in the CFTCR gene have been
described, but the most common mutation (noted in 70% of CF chromosomes) is DF508.
Alterations in the CFTCR gene result in deranged sodium and chloride ion transport
channels. This leads to failure of airway epithelia to hydrate their surfaces normally,
particularly in response to infectious or toxic insults. Additional effects include mucus
adhesion to airway surface, chronic inflammation, and infections. The concept that airway
surface dehydration can cause CF-like lung disease is supported by in vitro data and in vivo
animal models. Rehydrating airway surfaces may reduce or prevent lung injury and damage.
Short- and longer term studies have shown that inhalation of hypertonic saline is well
tolerated and improves lung function, reduces exacerbations, and improves quality of life in
CF patients. This review discusses the importance of airway epithelial sodium and chloride
channels in the pathogenesis of CF, and strategies (particularly the use of inhaled
hypertonic saline) to reverse or minimize lung inflammation and injury in this disease.
KEYWORDS: Cystic fibrosis, cystic fibrosis transmembrane conductance regulator
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The syndrome of cystic fibrosis (CF) reflects a
spectrum of more than 1400 mutations in the CF
transmembrane conductance regulator (CFTCR) gene.1
The CFTCR gene is large, 250 kb, and resides on
chromosome 7.2,3 The CFTCR protein encoded by the
CFTCR gene is a 1480 amino acid protein that typically
resides in the plasma membrane of epithelial cells.4 This
protein appears to have many functions, but a unifying
theme is that it acts at virtually all sites as a protein
kinase C and cyclic adenosine monophosphate (cAMP)-
regulated chloride (Cl) channel.5,6 Interestingly, in the
sweat duct, CFTCR acts as a Cl absorptive channel; in
the pancreas, it serves to secrete Cl, which is exchanged
for bicarbonate (HCO3); and in the lung, it is involved
in secretion of Cl. Importantly, in the lung, the
CFTCR protein has a second function acting as a
regulator of the epithelial sodium (Naþ) channel
(ENaC) and hence Naþ absorption.7,8
There are five classes of mutations in the CFTCR
gene that produce disease. The most common mutation,
which occurs on 70% of all CF chromosomes, is a three-
base-pair deletion that leads to a deletion of phenyl-
alanine at position 508 of the CFTCR protein and is
designated as DF508. The molecular pathogenesis of this
class of CFTCR mutations is relatively well understood.
Typically, the absence of a phenylalanine at position 508
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leads to problems in intracellular protein folding and
maturation that are part of the normal biosynthetic
pathway of membrane proteins.9,10 Consequently, the
DF508 CFTCR protein is ‘‘edited’’ out of the cell by
molecular chaperones and a variety of intracellular deg-
radative pathways. Hence, the molecular pathogenesis of
this most common form of CFTCRmutation reflects the
absence of a functioning CFTCR polypeptide in the
plasma membrane. Other mutations can produce a non-
functioning CFTCR Cl channel at the apical mem-
brane and/or a mutant CFTCR with abnormal ion
permeation characteristics.
CYSTIC FIBROSIS LUNG DISEASE
CF lung disease fundamentally reflects a failure in the
capacity of airway epithelia to normally hydrate their
surfaces, particularly in response to infectious or toxic
insults. Poor hydration of airway surfaces leads to re-
duced mucociliary clearance, adhesion of mucus to air-
way surfaces, and, ultimately, chronic bacterial infection
of airway surfaces (Fig. 1).
Data from an in vitro well-differentiated cell
culture model interfaced to a confocal microscope to
measure airway surface liquid (ASL) volume were key
in elucidating the importance of airway surface hydration
in lung defense.11,12 The hydration of the normal airway
surface (i.e., the volume of ASL), is determined in a
highly water-permeable epithelium such as airway epi-
thelia by ion transport processes that control the mass of
salt (NaCl) on airway surfaces.13 Normal airway epithelia
have the capacity to remove (absorb) NaCl from or add
(secrete) NaCl to airway surfaces (Fig. 2A). The absorp-
tive pathway reflects the capacity to actively absorb Naþ
ions, with Naþ entering the cell from ASL through the
ENaC. Naþ ions exit the cell via the activity of a
basolateral Naþ-Kþ-adenosine triphosphate (ATP)ase.
Chloride may be secreted from the cell by an apical
membrane CFTCR Cl channel or a Ca2þ -activated
Cl channel (CaCC), with Cl entering the cell princi-
pally via an Naþ-Kþ-2Cl- cotransporter. Regulation
of the balance between absorption and secretion deter-
mines the net transport of ions across the epithelium and,
hence, the mass of salt on an epithelial surface.
The processes that regulate the balance between
Naþ absorption and Cl secretion are beginning to be
elucidated (Fig. 2A). Important signals that are con-
tained within the ASL itself include the triphosphate
adenine nucleotide, ATP, and the adenine nucleoside,
adenosine (ADO).14 ATP, interacting with luminal
P2Y2 receptors, can slow the rate of Na
þ absorption
and initiate/accelerate Cl secretion via PKC-mediated
actions on CFTCR and Ca2þ-mediated actions on
CaCC.15 Adenosine can initiate Cl secretion via
cAMP-dependent activation of CFTCR and CFTCR-
dependent inhibition of ENaC. Recent data have sug-
gested that both systems are operative and important in
regulating the balance of Naþ absorption versus Cl
secretion in normal airway epithelia.16 The quantities of
ATP, and its metabolic product ADO, on airway surfa-
ces are determined by the mechanical stresses imparted
to airway epithelia during breathing that regulate the
rate of ATP release from epithelial cells into ASL.17 A
key concept is that the ATP signaling and the ADO
signaling systems are redundant and, hence, ensure
sufficient hydration under many conditions in the
normal lung.
CF airway epithelia are vulnerable to dehydration
because of the absence of the CFTCR protein in the
plasma membrane (Fig. 2B). Specifically, the adenosine-
A2b receptor system is functional, cAMP-dependent
activation of PKA is functional, but the absence of
CFTCR protein in the membrane renders the Cl
secretory and Naþ inhibitory effects of ADO signaling
ineffective. In contrast, the ATP-P2Y-R signaling sys-
tem is effective in CF airway epithelia in inhibiting
ENaC and initiating CaCC-mediated Cl secretion.15
In vitro studies demonstrate that, under conditions that
reprise tidal breathing in vivo, CF airway epithelia are
covered by sufficient ASL to mediate normal mucociliary
clearance, but they are missing a liquid reserve observed
on normal airway cells.16 Importantly, the CF hydration
capacity collapses if the lung is confronted with circum-
stances that degrade the efficacy of the ATP signaling
system. A relevant in vitro observation is that infection
of CF airway epithelia with paramyxoviruses, such as
respiratory syncytial virus (RSV), induces CF airway
epithelia to upregulate extracellular ATPase expres-
sion.16 This increased ATPase activity is sufficient
to degrade the ATP in ASL and diminish/abolish
P2Y2 inhibition of Na
þ absorption and stimulation of
Figure 1 Schema depicting relationship of Naþ and Cl trans-
port to mucus clearance and lung defense. (L) In health, Naþ
absorption and Cl secretion are coordinated to optimize airway
surface hydration and promote the clearance of mucus from
airway surfaces. (R) In cystic fibrosis, unregulated Naþ absorption
and diminished Cl secretion produce a propensity for airway
surface dehydration, mucus adhesion to airway surfaces, and,
ultimately, chronic inflammation and infection.
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CaCC-mediated Cl secretion. Under these conditions,
unregulated salt and liquid absorption occurs, the CF
airway surface becomes dehydrated, mucus transport is
abolished, and mucus stasis ensues. It has been specu-
lated that a similar event may occur in CF patients in
vivo during viral infections, leading to sludging of
dehydrated mucus in virus-infected areas of the lung
and spread of bacterial infection from bronchiectatic
areas to produce an acute exacerbation.18,19
The concept that airway surface dehydration can
produce CF-like lung disease was tested in an in vivo
model to ascertain whether the in vitro observations
cited here were pertinent to lung defense in vivo. As a
test of this hypothesis, subunits of the epithelial Naþ
channel were transgenically overexpressed in mice under
the control of an airway-specific promoter in an attempt
to tip the balance toward Naþ absorption over Cl
secretion.20 Analysis of the ion transport characteristics
of mice overexpressing the bENaC subunit revealed that
Naþ absorption was increased threefold over controls,
whereas the ability to generate Cl secretion in response
to nucleotide-activated CaCC activity was not per-
turbed. The disturbance of the balance between absorp-
tion and secretion produced the predicted depletion of
ASL volume, which resulted in mucus stasis, and death
due to mucus obstruction in 50% of transgenic ani-
mals. Unexpected but important findings were that the
reduction in ASL volume also produced neutrophilic
inflammation and goblet cell hyperplasia that are typical
features of CF lung disease. Thus, these observations
provided strong evidence that a disturbance of the
balance between Naþ absorption and Cl secretion, in
this case by transgenically raising Naþ transport rates
without disturbing Cl secretion, could produce airway
surface dehydration and a phenotype quite typical of
CF-like lung disease.
Finally, data from human clinical studies are
consistent with the notion that dehydration is a central
feature of CF lung disease.21–23 Clinical studies have also
employed inhaled hypertonic saline (HS), which osmoti-
cally draws water from epithelial cells/interstitium into
the airway lumen, to test whether this action restores
mucus clearance and improves pulmonary function.
Initial studies conducted approximately a decade ago
suggested that short-term (2 week) administration of
HS to CF patients was associated with an improvement
in lung function.24,25 More recently, a pair of papers
revealed that the inhalation of HS (7%, delivered by a jet
nebulizer) by CF patients over a 2-week period could
increase the rates of mucociliary clearance and improve
pulmonary function tests, and, over a 1-year interval,
reduce exacerbations and improve quality of life.26,27
Importantly, the inhalation of HS for 1 year was not
associated with any untoward events (e.g., increased
airways inflammation or increased bacterial densities).27
These studies have spurred intense interest in the pos-
sibility that HS and other ‘‘hydration therapies’’ may
provide a new form of therapy that treats CF lung
disease at its basic cause.
RATIONAL USE OF HYPERTONIC SALINE
There are many interesting and important concepts that
underlie the use of HS in CF subjects. The first is to
understand reasons why HS is more effective in CF
patients than in normal subjects. Second, it is important
to understand that HS probes the passive permeability
properties of the epithelium, and its actions should not
be confused with the functions of the epithelium under
physiological active ion transport modes. Some of these
important concepts can be evaluated in the context of
Fig. 3.
Beginning with normal airway epithelia, under
baseline conditions, when ASL Naþ and Cl concen-
trations are isotonic, Naþ is absorbed through ENaC in
response to the apical membrane–cellular electrochemical
Figure 2 Constitutive and shear-dependent release of adenine triphosphate (ATP) into airway surface liquid (ASL), coupled with
metabolic enzymes, produces levels of ATP and its metabolic product adenosine (ADO) that regulate the ion transport paths which
control the mass of salt and ultimately water on airway surfaces. (A) In normal airways, ATP signaling through P2Y2 receptors and ADO
signaling through A2b receptors provide redundant inhibition via the epithelial sodium channel (ENaC) (directly via P2Y2-R and indirectly
via A2b-CFTCR mechanisms) and regulation of both CFTCR- and CaCC-mediated Cl
 secretion. The typical net result is a modest rate of
NaCl and water absorption to remove ASL continually transported proximally from distal pulmonary regions. (B) In cystic fibrosis, the
absence of CFTCR function at the apical membrane removes the ADO contribution to inhibition of ENaC and the CFTCR contribution to
Cl secretion. Indeed, the ADO-A2b regulation is redirected toward activation of ENaC. The ATP-P2Y2-R system remains intact and is the
sole system to inhibit ENaC and regulate CaCC-mediated Cl secretion. The net effect is a tendency for increased and inappropriate
NaCl and water absorption. This residual form of regulation is vulnerable to any exogenous insults that perturb ASL ATP concentration.
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gradient favoring Naþ entry28,29 (Fig. 3A). Despite the
fact that there is a partially active CFTCRCl channel in
the apical membrane of the normal airway epithelium,
Cl is not absorbed with Naþ transcellularly, because
there is no electrochemical driving force for Cl move-
ment across the cell membrane.30–32 Thus, Cl is ab-
sorbed with Naþ via the paracellular path, in response to
the transepithelial electric potential difference (lumen
Figure 3 Ion and water transport under basal active ion transport conditions and after aerosol deposition of 7% NaCl on airway
surfaces. (A) Normal active ion transport: The net rate of active ion transport is determined by the rate of active Naþ transport, which is a
product of the electrochemical gradient favoring Naþ entry across the apical membrane (DFa
Naþ¼þ 60 mV) and Naþ extrusion across
the basolateral membrane by the NaþKþATPase pump. Because there is no net driving force for Cl flow through the apical membrane
CFTCR, Cl is absorbed paracellularly in response to the transepithelial electric potential difference (Vt) to preserve electroneutrality.
Water accompanies NaCl transport through cellular and paracellular paths. Note, ASL is isotonic; that is, [NaCl] ¼ 140 mM.39,40 (B)
Normal airways after hypertonic saline (HS) deposition. Airway surface liquid (ASL) NaCl concentrations are acutely raised (1000 mM
at 7%NaCl). The increased concentrations of Naþ and Cl increase the chemical driving force component for Naþ entry into the cell and
generate a large gradient favoring cellular Cl entry (i.e., absorption). The Naþ and Cl entering the cell exit the basolateral membrane via
the pump (Naþ), cotransporters (Naþ and Cl), and a basolateral Cl channel. In parallel, there is a relatively smaller increase in Naþ and
Cl absorption through the paracellular path, which is nonselective for ions, in response to the chemical gradients generated by HS
deposition. Water moves in the opposite direction in response to the transient NaCl osmotic gradient generated by HS deposition. (C)
Cystic fibrosis (CF) airway epithelial, active ion transport. The absence of CFTCR in the apical membrane removes a major inhibitor of the
epithelial sodium channel (ENaC), producing higher basal rates of Naþ transport and limiting the ability to regulate ENaC at low ASL
volumes. The high rate of Naþ transport generates a raised transepithelial potential difference (PD) (Vt), which provides the driving force
for Cl absorption via the paracellular path to match Naþ absorption. The raised net rate of NaCl absorption produces raised H2O
absorption and a tendency for ASL volume depletion (i.e., dehydration). (D) CF airway epithelia, post-HS deposition. Again, the
concentration of NaCl is raised in CF ASL by this maneuver to 1000 mM. Despite a large chemical driving force favoring Cl entry into
the cell from ASL, the absence of CFTCR in the membrane prevents entry of Cl into the cell. Despite the presence of a functioning
ENaC, transcellular Naþ absorption is limited by the block of cellular Cl entry. Therefore, virtually all the NaCl absorption occurs via the
paracellular path. Because NaCl absorption following HS deposition is limited to the paracellular path, it is slower, allowingmore time for
water to flow into the lumen in response to the persistent NaCl osmotic gradient. Thus, the ASL volume response to a given quantity of
HS deposition is greater in CF than in normal airways.
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negative) generated by active Naþ transport. Isotope flux
and ion-selective electrode data suggest that the overall
ion conductance of the cellular path is approximately
twofold greater than through the paracellular path in
normal airway epithelia.33,34 Recent data suggest that
water is absorbed with the actively transported Naþ and
Cl ions via cellular aquaporin water channels.
For illustrative purposes, we will assume that the
entire quantity of 7% HS is deposited undiluted on the
airway surface (note, the argument will hold with any
exogenously increased Naþ or Cl concentration in
ASL). It is important to note that the addition of
NaCl to airway surfaces via inhalation of hypertonic
NaCl is an artificial, unphysiological situation that
produces an exogenously induced Naþ and Cl chemical
gradient across the epithelium. In the normal airway
epithelium, the increase in Naþ concentration increases
the electrochemical driving force for Naþ to enter the
cell and generates the electrochemical driving force for
Naþ to move through the paracellular path (Fig. 3B).
Importantly, the increase in the Cl concentration in
ASL now generates an electrochemical driving force for
Cl to enter the cell via an active CFTCR and/or CaCC
Cl channel, with the residual Cl moving through the
paracellular path. The Naþ and Cl that enters the cell
in response to the aerosolized HS-induced NaCl con-
centration gradient on the airway surface exits the cell
through the basolateral Naþ-Kþ-ATPase, a basolateral
Cl channel, and likely through the Naþ-Kþ-2Cl
cotransporter. Based on the estimates of the relative
permeabilities of the cell and paracellular paths for
Naþ and Cl, it is estimated that approximately two
thirds of the NaCl may move through the transcellular
path in response to these imposed chemical gra-
dients.33,34 Note that the aerosol-induced increase in
NaCl concentration on airway surfaces produces a gra-
dient for water to move through water channels in the
opposite direction to that generated by active ion trans-
port (i.e., there is osmotically induced water flow from
the submucosa to the airway surface). Because NaCl is
absorbed rapidly through the normal cell as well as the
paracellular path after the imposition of the salt gradient,
the osmotic gradient generated by NaCl on normal
airway surfaces dissipates relatively rapidly, and only a
modest amount of water moves to airway surfaces in
response to this challenge (see Fig. 3B).
For CF airway epithelia, under baseline active ion
transport conditions, the rate of Naþ absorption is often
accelerated due to the absence of CFTCR-mediated
inhibition of ENaC (Fig. 3C). Interestingly, the absence
of the CFTCRCl conductance per se and the absence of
CFTCR inhibition of ENaC actually produces an elec-
trochemical driving force for Cl to be absorbed across
the apical membrane of CF airway epithelia.31,32 How-
ever, because of the absence of the CFTCR Cl channel
in this barrier, Cl must move through the paracellular
path to accompany the transcellular absorption of the
Naþ cation. The driving force that serves to match the
rate of transepithelial Cl absorption with Naþ absorp-
tion is the relatively high transepithelial potential differ-
ence (30 mV, lumen negative) generated by a high rate
of transcellular Naþ absorption. The increase of Naþ and
Cl transport in CF airway epithelia compared with
normal airway epithelia produces an increase in osmoti-
cally entrained water absorption from the airway lumen to
the submucosa via airway epithelial water channels.
In the case where an aerosol of 7% HS has been
used to increase the NaCl concentration on CF airway
surfaces, the differences in the passive ion permeabilities
of the CF airway epithelium versus normal airway
epithelium are revealed. As for normal airway epithelia,
when a high NaCl concentration in the ASL is gener-
ated by aerosol deposition of HS on ASL, an increase in
the electrochemical gradient for Naþ entry into the cell is
developed (Fig. 3D). Despite the fact that an increased
electrochemical gradient for cellular Cl entry is also
generated, Cl cannot enter the cell due to the absence
of the CFTCR Cl channel in the apical membrane.
The only available path for cellular Cl to be absorbed
across the CF airway epithelium, in response to the
chemical gradients generated by the deposition of
NaCl via aerosols in ASL, is the paracellular path.
Data from radioisotopic and electrophysiological
techniques suggest that the paracellular path permeabil-
ity to NaCl is not different in CF versus normal airway
epithelial cells.7,30–32,35 Therefore, because CF airway
epithelia can absorb the aerosol-deposited NaCl only via
the paracellular path, the rate of absorption/dissipation
of the salt gradient will be reduced by 60 to 70% as
compared with normal airway epithelia, reflecting the
absence of a cellular route for Cl absorption in CF
airway epithelia. The slower rate of NaCl absorption
leads to a relative retention of NaCl on CF airway
surfaces. Thus the osmotic gradient favoring water
flow generated by the aerosolized NaCl persists for
longer periods of time in CF than normal airway
epithelia, leading to increased volumes of water on CF
versus normal epithelial surfaces (see Fig. 3D). Interest-
ingly, this inability to absorb Cl passively via an
artificially imposed Cl gradient, producing increases
in ASL volume, may be the only ‘‘break’’ CF patients get
with respect to therapy of their lung disease.
Note, at the large NaCl concentration gradients
(10s to 100s mM) generated by HS deposition on CF
airway surfaces, the Cl conductance of the paracellular
path is limiting for Naþ and, hence, net NaCl absorption.
Under baseline conditions where CF active ion transport
determines ASL volume, active Naþ transport generates
mM salt gradients across CF airway epithelia. At phys-
iologic transport rates, the Cl conductance of the para-
cellular path is not limiting, so the rate of active Naþ
transport determines ASL volume. These considerations
HYPERTONIC SALINE THERAPY/TARRAN ET AL 299
resolve the apparent paradox of the importance of
the absent cellular CFTCR Cl conductance in the
response of the CF airway to aerosolized HS versus the
relative unimportance of the cellular Cl conductance in
the abnormal NaCl absorptive states that are a feature of
CF airways under basal conditions.
THE EFFECT OF AMILORIDE
PRETREATMENT ON HYPERTONIC SALINE
EFFICACY
An observation that led to some confusion and contro-
versy pertaining to the paper of Donaldson et al26 was
the fact that amiloride blunted the responses of CF
airway epithelia to HS36 (see Fig. 4A). It had been
predicted that by blocking the cellular path for Naþ
absorption, the amiloride-induced block of ENaC would
slow the active epithelial absorption of Naþ (and Cl)
across the epithelium. This effect was predicted to
promote a longer duration of the aerosolized HS depos-
ited on airway surfaces that would subsequently be
rendered isotonic via the osmotically driven movement
of water.37 Surprisingly, what was observed was that
administration of amiloride blocked the initial volume
response so that it was not possible to ascertain whether
amiloride slowed the subsequent active absorption of
ASL (Fig. 4A). Because it seemed implausible that
amiloride would accelerate the absorption of Naþ and
Cl across the CF airways epithelium, studies were
initiated to ascertain whether amiloride had a second
action on airway epithelial salt and water transport (e.g.,
blocked epithelial water permeability). These studies
Figure 4 Effect of amiloride on hypertonic saline (HS)-induced airway surface liquid (ASL) volume responses. (A) Confocal
measurements of ASL height/volume in cystic fibrosis (CF) airway epithelia in response to 7% HS without (&) and with (&) amiloride
(3 104 M) pretreatment. *Different from HS alone (p< .05). (B) Effect of amiloride on osmotically induced water flow across CF
airway epithelia. Cultured CF airway epithelia were placed on a confocal microscope with a fluorescent, impermeant probe in the
basolateral bath. At t¼ 0, hypertonic mannitol was placed in the luminal bath and the flow of water from the basolateral to the luminal
bath measured from the increase in serosal bath fluorescence (i.e., concentration of the serosal bath probe increased as water moved
into the luminal compartment). This assay was performed without (&) and with () amiloride (3104 M) administration to the lumen
10 minute prior to osmotic challenge. *Different from without amiloride pretreatment (p<0.05). (C) Speculated cellular action of
amiloride on transepithelial water flow after HS administration. The deposited HS produces the increase in ASL [NaCl], as depicted in
Fig. 3D. Again, the absence of a path for Cl absorption limits NaCl absorption to the paracellular path. It is speculated that amiloride
slows water flow in response to the HS-generated NaCl gradient by inhibiting aquaporin 5 in the apical membrane. This action allows
NaCl absorption to occur relatively more rapidly than water flow into the lumen, greatly decreasing the ASL volume expansion in
response to HS administration.
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revealed that amiloride at high concentrations blocked
transepithelial water flows in response to osmotic gra-
dients generated by added NaCl or a nonionic solute,
mannitol (Fig. 4B). Although the precise mechanisms
are not known, it appears from subsequent studies that
amiloride may block the aquaporin 5 channel that is an
important water channel in the apical membrane of
normal and CF airway epithelia. Thus, as shown in
Fig. 4C, a partial block of the apical membrane water
channel slows water movement toward the lumen in
response to the aerosol-imposed NaCl gradient, allow-
ing the NaCl gradient to be dissipated through the
paracellular path. Thus the ‘‘kinetic horse race’’ between
the absorption of NaCl via the paracellular path versus
the movement of water toward the lumen via the cellular
path is tipped in favor of paracellular NaCl absorption
via the actions of amiloride. The net effect is a reduced
volume response to the aerosol-generated salt gradient.
Interestingly, amiloride might have been thera-
peutically useful if given after HS rather than as a
pretreatment. That is, amiloride would have blocked
the active absorption of Naþ (and Cl). Because, as
noted earlier, the gradients of NaCl across the epithe-
lium generated by active Naþ (and Cl) absorption are
very low (mM) as compared with aerosol deposition of
salt (mM), any amiloride block of water flow would have
negligible effects on osmotic water flow coupled to active
ion transport. However, the clinical utility of delivering
amiloride after HS may be minimal because the half-life
of amiloride on airway surfaces is short (30 min).
THE FUTURE OF HYDRATION THERAPIES
A central question will be the position of HS within the
spectrum of therapies available to CF patients. On one
level, because HS may treat the initiating cause of CF
lung disease, it may make sense to make HS the ‘‘base’’
therapy for CF patients. However, the current experi-
ence principally reflects administration of HS with
pressure-driven nebulizers to adolescents and young
adults . Studies are under way to transition the delivery
of HS to more time-efficient devices (e.g., ultrasonic
devices) that can also be more easily interfaced to infants.
Thus important studies that will soon be initiated are
ones designed to test whether inhaled HS in infants over
a 1-year period can forestall the decrements in lung
function and the abnormalities in CT (air trapping/
bronchiectasis) that characterize this period. Similar
studies are under way in 4- to 6-year-old cohorts to
ascertain whether HS can arrest the decrement of lung
function typically seen in this age group.
Because the initiating events of many acute ex-
acerbations in CF are viral infections that may induce
mucus sludging in airways that were previously ‘‘quasi-
normally’’ hydrated via the actions of ATP (see earlier),
it may make sense to study relationships between HS
therapy and exacerbations. Because this thesis has not
been tested, it will be important to generate randomized
trials to ascertain whether maximization of HS therapy
at the time the CF patient clinically senses a ‘‘virus’’ will
forestall an exacerbation. In parallel, studies may also be
warranted to test whether maximization of HS-medi-
ated hydration will shorten the interval of the exacer-
bation and improve the outcome of therapy for
exacerbations.
Finally, HS does have limitations with respect to
the therapy of CF lung disease. For example, HS at 7%
can be irritating to some patients and cause broncho-
constriction. Similarly, particularly in children, the taste
of HS is a detriment to chronic use of this agent. Perhaps
most importantly, it is difficult to deliver HS efficiently
to the very large surface area of the small airways/
bronchioles that appear to be the site of initiation of
CF lung disease.38–40 This phenomenon reflects the
simple aerosol physics parameters of the modern nebu-
lizer, which deposits approximately equal volumes of
aerosol on the relatively small surface area of central
airways compared with the relatively large surface area of
small airways. Because the hydration effect of HS is a
linear function of the amount of salt deposited on airway
surfaces, the small airways will always be less well treated
by HS. Thus, it may be advantageous in the future to
utilize approaches that hydrate airway surfaces by induc-
ing secretion of NaCl via receptor-mediated pathways
that can be fully activated by potent ligands delivered to
small airway surfaces, for example, stabilized nucleotide
molecules (INS37217), or by the coadministration of
new, potent, long-acting Naþ channel blockers that will
retain all NaCl added to small airway surfaces to amplify
the hydrating effects of HS in this region. It is likely that
the requirement to effectively treat the bronchiole will be
a central feature of any hydrating regimen to, in a most
assured fashion, prevent and/or arrest the progression of
lung disease in CF patients.
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